199469-91-5

Basic information

• Product Name: Benzeneacetic acid, 4-nitro-2-(trifluoromethyl)-
• Synonyms: 4-Nitro-2-(trifluoromethyl)phenylacetic acid;Benzeneacetic acid, 4-nitro-2-(trifluoromethyl)-
• CAS NO: 199469-91-5
• Molecular Formula: C₉H₆F₃NO₄
• Molecular Weight: 249.14
• Mol File: 199469-91-5.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzeneacetic acid, 4-nitro-2-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, 4-nitro-2-(trifluoromethyl)-(199469-91-5)
• EPA Substance Registry System: Benzeneacetic acid, 4-nitro-2-(trifluoromethyl)-(199469-91-5)

Safety Data

• Hazardous Substances Data: 199469-91-5(Hazardous Substances Data)

Upstream product

• 3038-47-9 2-(trifluoromethyl)phenylacetonitrile 

Downstream Products

• 853297-71-9 N-[4-(6-chloro-pyrimidin-4-yloxy)-phenyl]-N'-{4-[2-(4-ethyl-piperazin-1-yl)-ethyl]-3-trifluoromethyl-phenyl}-urea 
• 853297-74-2 2-(4-amino-2-trifluoromethyl-phenyl)-1-(4-ethyl-piperazin-1-yl)-ethanone 
• 853297-73-1 2-(4-nitro-2-trifluoromethyl-phenyl)-1-(4-ethyl-piperazin-1-yl)-ethanone 
• 853297-72-0 4-[2-(4-ethyl-piperazin-1-yl)-ethyl]-3-trifluoromethyl-phenylamine 

Relevant articles and documents

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.